Stock comparison
IDEXX Laboratories
Indivior Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
INDV
Indivior Pharmaceuticals
Market cap
$4.68B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | INDV | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 35D | IDXX |
| Benjamin Graham | 80A | 30F | IDXX |
| Philip Fisher | 75B | 44D | IDXX |
| Peter Lynch | 71B | 71B | Tie |
| Joel Greenblatt | 83C | 78B | IDXX |
| Charlie Munger | 87A | 50D | IDXX |
| Terry Smith | 84A | 46D | IDXX |
Side-by-side metrics
| Metric | IDXX | INDV |
|---|---|---|
| Market cap | $44.12B | $4.68B |
| P/E (TTM) | 39.0x | 19.0x |
| EV/EBIT | 31.6x | 19.1x |
| ROIC (TTM) | 40.66% | 85.68% |
| Gross margin | 62.05% | 83.11% |
| Net margin | 24.63% | 19.44% |
| Revenue CAGR 5y | 7.56% | 11.87% |
| EPS CAGR 5y | 10.79% | 5.04% |
| Debt / Equity | 0.7x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.12Bvs $4.68B+89%
- EPS CAGR 5y10.79%vs 5.04%+53%
- Net margin24.63%vs 19.44%+21%
INDV leads on
- Debt / Equity-vs 0.7x+120%
- ROIC (TTM)85.68%vs 40.66%+53%
- P/E (TTM)19.0xvs 39.0x+51%
- EV/EBIT19.1xvs 31.6x+39%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.